Moberg Pharma Valuation
Is MOB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MOB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MOB (SEK15.6) is trading below our estimate of fair value (SEK38.15)
Significantly Below Fair Value: MOB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MOB?
Other financial metrics that can be useful for relative valuation.
| What is MOB's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 82.5x |
| Enterprise Value/EBITDA | -14x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does MOB's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9x | ||
IRLAB A IRLAB Therapeutics | 18.8x | 23.7% | SEK 713.2m |
LIPI Lipidor | 6.7x | n/a | SEK 109.4m |
ERMA Enorama Pharma | 6x | n/a | SEK 232.2m |
ENZY Enzymatica | 4.4x | 62.6% | SEK 312.1m |
MOB Moberg Pharma | 0.8x | 85.5% | SEK 728.4m |
Price-To-Book vs Peers: MOB is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (9x).
Price to Earnings Ratio vs Industry
How does MOB's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?
Price-To-Book vs Industry: MOB is good value based on its Price-To-Book Ratio (0.8x) compared to the Swedish Pharmaceuticals industry average (4.2x).
Price to Book Ratio vs Fair Ratio
What is MOB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate MOB's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.